Antifungal meds cut risk for death after lung transplant

Antifungal meds cut risk for death after lung transplant

(HealthDay)—Preventive antifungal medications cut the risk for death following a lung transplant by more than half, according to a study published online Sept. 23 in the Annals of the American Thoracic Society.

Kelly M. Pennington, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues evaluated the effect of prophylaxis on all-cause mortality and invasive fungal infections (IFI) in patients. The analysis included 667 recipients (385 received prophylaxis and 282 did not) who were identified through administrative claims data (2005 through 2018).

The researchers found that all-cause mortality was significantly lower in those receiving antifungal prophylaxis versus those not (event rate per 100 person-years: 8.77 versus 18.50; hazard ratio, 0.48; 95 percent confidence interval, 0.26 to 0.71; P = 0.003). There were also lower rates of IFI seen among patients receiving antifungal prophylaxis versus those not receiving prophylaxis (event rate per 100 person-years: 15.09 versus 22.48; hazard ratio, 0.68; 95 percent confidence interval, 0.45 to 1.05; P = 0.08).

"This is the first study to demonstrate a mortality benefit associated with the use of antifungal prophylaxis in lung transplant patients," Pennington said in a statement. "We still do not know which lung transplant patients receive the most benefit from these medications, and there are other unanswered questions that will require more research."


Explore further

Study finds lung transplant patients not given antifungal preventive drugs have higher risk of death

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved.

Citation: Antifungal meds cut risk for death after lung transplant (2020, October 26) retrieved 27 November 2020 from https://medicalxpress.com/news/2020-10-antifungal-meds-death-lung-transplant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments